As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...

Biohaven's $600M financing deal, Protara's cell therapy data, Pfizer's bladder cancer success, plus news from CG Oncology, ...

Boehringer Ingelheim's zongertinib shows promising results in lung cancer trial with 71% response rate and 14-month median ...

France’s national public health agency is suspending immunization of adults 65 years and older with Valneva’s chikungunya ...

Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...

Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...

Revolution Medicines' zoldonrasib shows 61% response rate in lung cancer patients with KRAS G12D mutations in Phase 1 trial, ...

Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.

HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to ...

Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a ...

A federal district court in Texas on Thursday denied a request for a preliminary injunction from the Outsourcing Facilities ...

Amgen is the latest in a series of biopharma companies to tout a massive new US-based investment in manufacturing.